Do COX-2 inhibitors reduce metachronous cancer development? Joseph R. Pisegna Clinical Trials Report 29 November 2009 Pages: 429 - 430
Gastric acid hypersecretory states: Recent insights and advances Nauramy OsefoTetsuhide ItoRobert T. Jensen OriginalPaper 29 November 2009 Pages: 433 - 441
Gut sensing mechanisms Arushi deFonsekaJonathan Kaunitz OriginalPaper 29 November 2009 Pages: 442 - 447
Regulation of food intake: The gastric X/A-like endocrine cell in the spotlight Andreas StengelYvette Taché OriginalPaper 29 November 2009 Pages: 448 - 454
Gastric infection by Helicobacter pylori George SachsYi WenDavid R. Scott OriginalPaper 29 November 2009 Pages: 455 - 461
Gastric acid inhibition in the treatment of peptic ulcer hemorrhage Kevin A. GhassemiThomas O. G. KovacsDennis M. Jensen OriginalPaper 29 November 2009 Pages: 462 - 469
Insights into IBD pathogenesis David Q. ShihStephan R. Targan OriginalPaper 29 November 2009 Pages: 473 - 480
Natural history and complications of IBD Morten H. Vatn OriginalPaper 29 November 2009 Pages: 481 - 487
Diagnostic advances in inflammatory bowel disease (imaging and laboratory) Maria E. MoscandrewEdward V. Loftus Jr OriginalPaper 29 November 2009 Pages: 488 - 495
Optimizing conventional therapies for inflammatory bowel disease Miles P. SparrowPeter M. IrvingStephen B. Hanauer OriginalPaper 29 November 2009 Pages: 496 - 503
Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and crohn’s disease) Marc FerranteGeert D’HaensGert Van Assche OriginalPaper 29 November 2009 Pages: 504 - 508
Managing the risks of IBD therapy Cynthia H. SeowShanika de SilvaRemo Panaccione OriginalPaper 29 November 2009 Pages: 509 - 517